HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: indications for central and peripheral mechanisms.

Abstract
A promising target for memory improvement is phosphodiesterase type 5 (PDE5), which selectively hydrolyzes cyclic guanosine monophosphate (cGMP). In rodents, PDE5 inhibitors (PDE5-Is) have been shown to improve memory performance in many behavioral paradigms. However, it is questioned whether the positive effects in animal studies result from PDE5 inhibition in the central nervous system or the periphery. Therefore, we studied the effects of PDE5 inhibition on memory and determined whether compound penetration of the blood-brain barrier (BBB) is required for this activity. Two selective PDE5-Is, vardenafil and UK-343,664, were tested in the object recognition task (ORT) in both a MK-801- and scopolamine-induced memory deficit model, and a time-delay model without pharmacological intervention. Compounds were dosed 30 min before the learning trial of the task. To determine if the PDE5-Is crossed the BBB, their concentrations were determined in plasma and brain tissue collected 30 min after oral administration. Vardenafil improved object recognition memory in all three variants of the ORT. UK-343,664 was ineffective at either preventing MK-801-induced memory disruption or time-dependent memory decay. However, UK-343,664 attenuated the memory impairment of scopolamine. Vardenafil crossed the BBB whereas UK-343,664 did not. Further, co-administration of UK-343,664 and scopolamine did not alter the brain partitioning of either molecule. This suggests that the positive effect of UK-343,664 on scopolamine-induced memory decay might arise from peripheral PDE5 inhibition. The results herein suggest that there may be multiple mechanisms that mediate the efficacy of PDE5 inhibition to improve memory performance in tasks such as the ORT and that these involve PDE5 located both within and outside of the brain. To further elucidate the underlying mechanisms, the cellular and subcellular localization of PDE5 needs to be determined.
AuthorsOlga A H Reneerkens, Kris Rutten, Sven Akkerman, Arjan Blokland, Christopher L Shaffer, Frank S Menniti, Harry W M Steinbusch, Jos Prickaerts
JournalNeurobiology of learning and memory (Neurobiol Learn Mem) Vol. 97 Issue 4 Pg. 370-9 (May 2012) ISSN: 1095-9564 [Electronic] United States
PMID22426465 (Publication Type: Journal Article)
CopyrightCopyright © 2012 Elsevier Inc. All rights reserved.
Chemical References
  • Imidazoles
  • Phosphodiesterase 5 Inhibitors
  • Piperazines
  • Pyrimidinones
  • Sulfones
  • Triazines
  • UK 343,664
  • Vardenafil Dihydrochloride
  • Dizocilpine Maleate
  • Scopolamine
  • Cyclic Nucleotide Phosphodiesterases, Type 5
Topics
  • Animals
  • Blood-Brain Barrier
  • Cyclic Nucleotide Phosphodiesterases, Type 5 (drug effects, physiology)
  • Dizocilpine Maleate (pharmacokinetics, pharmacology)
  • Imidazoles (pharmacokinetics, pharmacology)
  • Male
  • Phosphodiesterase 5 Inhibitors (pharmacokinetics, pharmacology)
  • Piperazines (pharmacokinetics, pharmacology)
  • Pyrimidinones (pharmacokinetics, pharmacology)
  • Rats
  • Rats, Wistar
  • Recognition, Psychology (drug effects, physiology)
  • Scopolamine (pharmacokinetics, pharmacology)
  • Sulfones (pharmacokinetics, pharmacology)
  • Triazines (pharmacokinetics, pharmacology)
  • Vardenafil Dihydrochloride

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: